Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as expected in the third quarter of this year.

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Regneron stock crashed today following disappointing COPD trials data. Here's what makes REGN shares worth buying on the ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Kymera Therapeutics reported that an experimental drug designed to rival Sanofi and Regeneron’s blockbuster therapy Dupixent ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

US biotech Regeneron Pharmaceuticals has announced detailed analyses from the Phase III C-POST trial, which evaluated PD-1 ...

US biotech Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced a strategic in-licensing agreement with China’s ...